Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2026. The increasing momentum of our portfolio focus has resulted in Evolus gaining...
Business Wire
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme in Canada, Australia, and New Zealand
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expanded its partnership with Symatese through an amendment to the companies existing licensing and distribution agreement, providing Evolus...
Business Wire
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of +33.33% and +5.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Evolus to Report Second Quarter Financial Results on August 5, 2026
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.Evolus management will...
Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the companys common stock to 38 newly hired non-executive...
Business Wire
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics PR Newswire RENO, Nev., July 9, 2026 Issued on behalf of Conexeu Sciences Inc.Conexeu...
PR Newswire
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo in the United States, Expanding Its Injectable Portfolio into Skin Quality
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and...
Business Wire
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
Notable Wednesday Option Activity: EOLS, PRCH, ZS
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Evolus Inc (Symbol: EOLS), where a total volume of 4,005 contracts has been traded thus far today, a contract volume which is representative of approximately 400...
Nasdaq News: Markets
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It PR Newswire NEW YORK, May 22, 2026 Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ...
PR Newswire